RP6306 selectively inhibits PKMYT1 and suppresses tumor growth in CCNE1-amplified cancers.54 Known for its oral bioavailability, RP6306 is currently being evaluated in clinical trials, such as the MYTHIC trial (NCT04855656). Here, CCNE1 is linked to neoplasm.